Prediction of Human Pharmacokinetics of Bendamustine from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles

Abstract

Bendamustine, an alkylating anticancer agent, is used to treat chronic lymphocytic leukemia by intravenous infusion alone or in combination. The work aimed to develop a method to predict time vs. concentration profile for humans based on preclinical pharmacokinetics using the assumption of superimposability of normalized time course profiles of animals and humans. Standard allometric equations with/without correction factors (CF) were also used in prediction. The Vss was predicted by simple allometry of 0.312W^0.871 (r²=0.987), where W is body weight; predicted Vss (19.71 L) was similar to the reported value (20.10 L). However, CL prediction involved both simple and CF allometry. Best proximity CL (543 vs. 598 mL/min) was obtained with maximum life span correction (MLP) [2.46W^1.215 (r²=0.988)]. Normalized curves were obtained by normalizing the time (with mean residence time) vs. concentration (with dose/Vss) in animal species. The concentration vs. time profile in humans after intravenous infusion was then simulated using normalized curve for each animal species and the values of CL and Vss were predicted for humans. In summary the findings indicate that normalized time course approach could predict the bendamustine human pharmacokinetics and such an approach could be prospectively applied for analog drugs of this class.

Key words

Bendamustine - preclinical pharmacokinetics - clinical pharmacokinetics - interspecies scaling - simulations - normalized curve

• References

• 1 Leoni LM. Bendamustine: Rescue of an effective antineoplastic agent from the mid-twentieth century. Semin Hematol 2011; 48 (Suppl. 01) S4-S11
• 2 AusPAR Ribomustin. (2015). Bendamustine hydrochloride. Janssen-Cilag Pty Ltd PM-2013-01517-1-4
• 3 Teichert J, Baumann F, Chao Q. et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2007; 59: 759-770
• 4 Dubbelman AC, Rosing H, Darwish M. et al. Pharmacokinetics and excretion of ¹⁴C-bendamustine in patients with relapsed or refractory malignancy. Drugs R D 2013; 13: 17-28
• 5 BENDEKA ® . Bendamustine hydrochloride injection - Current Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc;
• 6 Wajima T, Yano Y, Fukumura K. et al. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci 2004; 93: 1890-1900
• 7 Chandrashekar DV, Suresh PS, Kumar R. et al. Sensitive LC-MS/MS method for the simultaneous determination of bendamustine and its active metabolite, γ-hydroxybendamustine in small volume mice and dog plasma and its application to a pharmacokinetic Study in mice and dogs. Drug Res 2017; 67: 497-508
• 8 https://www.digitizeit.de/. Accessed 10 Feb. 2018
• 9 Drager AS, Labell AY, Patel PR. Liquid formulations of bendamustine. 2014. US patent: US 20140206733A1
• 10 Ward KW, Smith BR. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 2004; 32: 603-611
• 11 Nagilla R, Ward KW. A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci 2004; 93: 2522-2534
• 12 Boxenbaum H. Interspecies scaling, physiological time and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982; 10: 201-227
• 13 Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 1984; 15: 1071-1021
• 14 Mahmood I. Pharmacokinetic allometric scaling of antibodies: Application to the first-in-human dose estimation. J Pharm Sci 2009; 98: 3850-3861
• 15 Srinivas NR. Allometry as a tool in drug development: Case studies, perspectives and general considerations. In: Drug development perspectives-considerations, challenges and strategies. edited by Srinivas NR. HNB Publishing New York: HNB Publishing; 2010. pp 47-106
• 16 Pavankumar VV, Vinu CA, Mullangi R. et al. Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator. Eur J Drug Metab Pharmacokinet 2007; 32: 29-37
• 17 Ahlawat P, Srinivas NR. Allometric prediction of the human pharmacokinetic parameters for naveglitazar. Eur J Drug Metab Pharmacokinet 2008; 33: 187-190
• 18 Ahlawat P, Srinivas NR. Interspecies scaling of a camptothecin analogue: Human predictions for intravenous topotecan using animal data. Xenobiotica 2008; 38: 1377-1385
• 19 Mullangi R, Ahlawat P, Trivedi RK. et al. Use of bile correction factors for allometric prediction of human pharmacokinetic parameters of torcetrapib, a facile cholesteryl ester transfer protein inhibitor. Eur J Drug Metab Pharmacokinet 2009; 34: 57-63
• 20 Gilbili RR, Mullangi R, Srinivas NR. Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometric approach. Eur J Drug Metab Pharmacokinet 2011; 36: 87-93
• 21 Gilibili RR, Bhamidipati RK, Mullangi R. et al. Retrospective and prospective human intravenous and oral pharmacokinetic projection of DPP-IV inhibitors using simple allometric principles – case Studies of ABT-279, ABT-341, alogliptin, carmegliptin, sitagliptin and vildagliptin. J Pharm Pharm Sci 2015; 18: 434-447
• 22 Bhamidipati RK, Gurav S, Police A. et al. The human pharmacokinetics of odanacatib predicted by inter species scaling - A retrospective analysis. Int J Pharmacokine 2017; 2: 47-55
• 23 Bhamidipati RK, Mullangi R, Srinivas NR. Interspecies scaling of urinary excretory amounts of nine drugs belonging to different therapeutic areas with diverse chemical structures - accurate prediction of the human urinary excretory amounts. Xenobiotica 2017; 47: 112-118
• 24 Mahmood I. Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv Drug Deliv Rev 2007; 59: 1177-1192
• 25 Lombardo F, Berellini G, Labonte LR. et al. Systematic evaluation of Wajima superposition (steady-state concentration to mean residence time) in the estimation of human intravenous pharmacokinetic profile. J Pharm Sci 2016; 105: 1277-1287